Alternativas no farmacológicas en la insuficiencia o falla cardíaca

Ana M. Jerez Castro

Texto completo:

HTML PDF PDF (English)

Resumen

Las opciones terapéuticas son limitadas para los pacientes con insuficiencia cardíaca avanzada que se vuelven refractarios a las terapias farmacológicas convencionales. Conocer las alternativas no farmacológicas en el tratamiento de estos enfermos resulta imprescindible en su evaluación integral, y es la segunda opción terapéutica en este grupo de enfermos cada vez más prevalentes.

Referencias

Centers for Disease Control and Prevention. Ambulatory Health Care Data: Questionnaires, Datasets, and Related Documentation [Internet]. Atlanta: National Center for Health Statistics [citado 17 Feb 2019]. Disponible en: https://www.cdc.gov/nchs/ahcd/ahcd_questionnaires.htm

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776-803.

Bhagra SK, Pettit S, Parameshwar J. Cardiac transplantation: indications, eligibility and current outcomes. Heart. 2019;105(3):252-60.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Rev Esp Cardiol [Internet]. 2016 [citado 17 Feb 2019];69(12):1167.e1-e85. Disponible en: https://www.revespcardiol.org/es-pdf-S0300893216305541

Plácido R, Mebazaa A. Tratamiento no farmacológico de la insuficiencia cardiaca aguda. Rev Esp Cardiol. 2015;68(9):794-802.

Berbenetz N, Wang Y, Brown J, Godfrey C, Ahmad M, Vital FM, et al. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev [Internet]. 2019 [citado 19 Feb 2019];4(4):CD005351. Disponible en: http://doi.org/10.1002/14651858.CD005351.pub4

Comité Organizador Comisión de Normatizaciones y Consensos (SAC). Consenso de asistencia circulatoria mecánica. Rev Argent Cardiol. 2004;72(1):37-51.

Feldmann C, Chatterjee A, Haverich A, Schmitto JD. Left ventricular assist devices - A state of the art review. En: Islam S, ed. Heart Failure: From Research to Clinical Practice. Cham (Suiza): Springer International Publishing; 2018. p. 287-294.

Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49(6):675-83.

Portolés Pérez J, Cuevas Bou X. Síndrome cardiorrenal. Nefrología. 2008;28(Supl. 3):29-32.

François K, Ronco C, Bargman JM. Peritoneal dialysis for chronic congestive heart failure. Blood Purif. 2015;40(1):45-52.

Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol. 2005;45(3):381-7.

Sievert H, Schofer J, Ormiston J, Hoppe UC, Meredith IT, Walters DL, et al. Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. EuroIntervention. 2015;10(10):1213-20.

Marín-Orozco IC, Cardona-Vélez J, Jaramillo-Restrepo V, Echeverri-Isaza S, Jaramillo-Gómez NI. Denervación renal percutánea mediante el uso de catéter con balón en pacientes con hipertensión arterial resistente. Rev Colomb Cardiol. 2015;22(6):305-11.

Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368(17):1585-93.

Woods B, Hawkins N, Mealing S, Sutton A, Abraham WT, Beshai JF, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart. 2015;101(22):1800-6.

Ojo A, Tariq S, Harikrishnan P, Iwai S, Jacobson JT. Cardiac resynchronization therapy for heart failure. Interv Cardiol Clin. 2017;6(3):417-26.

Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83.

Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292(23):2874-9.

Raphael CE, Finegold JA, Barron AJ, Whinnett ZI, Mayet J, Linde C, et al. The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most? Eur Heart J. 2015;36(26):1676-88.

Martín Gutiérrez E, Martínez Comendador JM, Martínez Paz E. Reparación quirúrgica de rotura ventricular izquierda postinfarto mediante técnica de Dor modificada. Cir Cardiov.2016;23(4):212.

Stewart GC, Givertz MM. Mechanical circulatory support for advanced heart failure: patients and technology in evolution. Circulation. 2012;125(10):1304-15.

Schmidt M, Burrell A, Roberts L, Bailey M, Sheldrake J, Rycus PT, et al. Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score. Eur Heart J. 2015;36(33):2246-56.

Hidalgo Díaz JR, Hernández Cañero A, Chachques JC, Paredes Cordero A. Células madre mesenquimales de médula ósea y de cordón umbilical en el tratamiento de enfermedades cardiovasculares. CorSalud [Internet] 2018 [citado 22 Feb 2019];10(1):47-51. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/view/294/628

Schächinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol. 2004;44(8):1690-9.

Planat-Bénard V, Menard C, André M, Puceat M, Perez A, Garcia-Verdugo JM, et al. Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ Res. 2004;94(2):223-9.

Assmus B, Honold J, Schächinger V, Britten MB, Fischer-Rasokat U, Lehmann R, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006;355(12):1222-32.

Chachques JC, Herreros Gonzalez J, Trainini JC. Cardiomioplastia celular. Rev Argent Cardiol. 2003;71(2):138-45.

Floras JS. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol. 2009;54(5):375-85.

Zannad F, De Ferrari GM, Tuinenburg AE, Wright D, Brugada J, Butter C, et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J. 2015;36(7):425-33.

Lopshire JC, Zipes DP. Device therapy to modulate the autonomic nervous system to treat heart failure. Curr Cardiol Rep. 2012;14(5):593-600.

Swynghedauw B. Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles. Physiol Rev. 1986;66(3):710-71.

Hung CL, Verma A, Uno H, Shin SH, Bourgoun M, Hassanein AH, et al. Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol. 2010 Nov 23;56(22):1812-22.

Lee RJ, Hinson A, Helgerson S, Bauernschmitt R, Sabbah HN. Polymer-based restoration of left ventricular mechanics. Cell Transplant. 2013;22(3):529-33.

Lee LC, Zhihong Z, Hinson A, Guccione JM. Reduction in left ventricular wall stress and improvement in function in failing hearts using Algisyl-LVR. J Vis Exp [Internet]. 2013 [citado 27 Feb 2019];(74):50096. Disponible en: https://www.jove.com/pdf/50096

Anker SD, Coats AJ, Cristian G, Dragomir D, Pusineri E, Piredda M, et al. A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial). Eur Heart J. 2015;36(34):2297-309.

Mann DL, Lee RJ, Coats AJ, Neagoe G, Dragomir D, Pusineri E, et al. One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure. Eur J Heart Fail. 2016;18(3):314-25.

Banner NR, Bonser RS, Clark AL, Clark S, Cowburn PJ, Gardner RS, et al. UK guidelines for referral and assessment of adults for heart transplantation. Heart. 2011;97(18):1520-7.

Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates – 2006. J Heart Lung Transplant. 2006;25(9):1024-42.

Enlaces refback

  • No hay ningún enlace refback.


Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.